Core Viewpoint - A class action securities lawsuit has been filed against Treace Medical Concepts, Inc. alleging securities fraud affecting investors between May 8, 2023, and May 7, 2024 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Treace Medical Concepts, Inc. made false statements regarding the impact of competition on the demand for its primary product, the 3D bunion correction system, "Lapiplasty" [2]. - It is alleged that due to competition, Treace Medical's revenue declined, prompting the company to accelerate plans for an alternative product to osteotomy [2]. - The defendants' positive statements about the company's business and prospects were claimed to be materially misleading and lacked a reasonable basis [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until June 10, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - Treace Medical Concepts, Inc. (NASDAQ: TMCI) is facing a class action lawsuit due to allegations of issuing materially false and misleading statements regarding its primary product, the 3D bunion correction system, "Lapiplasty" [3]. Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from May 8, 2023, to May 7, 2024 [3]. - Allegations include that competition negatively impacted the demand for the Lapiplasty system, leading to a decline in Treace Medical's revenue [3]. - The company needed to accelerate plans for an alternative product to osteotomy due to these challenges [3]. - Defendants' positive statements about the company's business and prospects were claimed to be materially misleading [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by June 10, 2025, to participate in potential recovery [4]. - Registration will include enrollment in a portfolio monitoring software for status updates throughout the case [4]. Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Core Viewpoint - A class action lawsuit has been filed against Treace Medical Concepts, Inc. for alleged violations of securities laws, specifically related to misleading statements about the company's performance and competition affecting its products [1][4]. Group 1: Lawsuit Details - The lawsuit is based on violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1]. - Investors who purchased Treace's securities between May 8, 2023, and May 7, 2024, are encouraged to participate in the lawsuit [2]. - The class has not yet been certified, meaning potential participants are not currently represented by an attorney [3]. Group 2: Company Performance - Treace Medical Concepts faced competition that negatively impacted its Lapiplasty 3D Bunion Correction System, leading to a decline in revenue [4]. - The company felt compelled to accelerate plans to offer an alternative osteotomy solution due to these challenges [4]. - Public statements made by Treace during the class period were deemed false and materially misleading, resulting in investor damages when the truth was revealed [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Treace Medical Concepts, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on June 10, 2025 [1]. Group 1: Class Action Details - Investors who purchased Treace Medical securities between May 8, 2023, and May 7, 2024, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The lawsuit claims that Treace Medical made false or misleading statements regarding its business operations and the demand for its primary product, the Lapiplasty 3D Bunion Correction System [5]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements in the past, including over $438 million for investors in 2019 and has been recognized as a leader in the field [4]. Group 3: Case Specifics - The lawsuit alleges that competition negatively impacted the demand for Treace Medical's primary product, leading to a decline in revenue and a need to accelerate alternative product offerings [5]. - The misleading statements made by the defendants resulted in investor damages when the true situation was revealed [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Treace Medical Concepts, Inc. due to allegations of misleading statements and failure to disclose important information regarding competition and revenue guidance [3][5]. Group 1: Allegations Against Treace Medical - The complaint alleges that Treace Medical and its executives violated federal securities laws by making false and misleading statements [5]. - Key issues include the impact of competition on the demand for Treace's primary product, the Lapiplasty 3D Bunion Correction System, leading to a decline in revenue [5]. - The company had to accelerate plans for an alternative product to osteotomy due to competitive pressures [5]. Group 2: Revenue Guidance and Stock Impact - On May 7, 2024, Treace Medical lowered its full-year 2024 revenue guidance from $220 million-$225 million to $201 million-$211 million [6]. - Following this announcement, the company's stock price fell by $6.95, or nearly 63%, closing at $4.17 per share on May 8, 2024, with unusually high trading volume [7]. Group 3: Legal Proceedings and Class Action - Investors who suffered losses are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options [1][9]. - There is a June 10, 2025 deadline for investors to seek the role of lead plaintiff in the federal securities class action against Treace Medical [3].

Core Viewpoint - A class action securities lawsuit has been filed against Treace Medical Concepts, Inc. due to alleged securities fraud impacting investors between May 8, 2023, and May 7, 2024 [1][2] Group 1: Allegations and Impact - The lawsuit claims that Treace Medical Concepts concealed the impact of competition on the demand for its primary product, the 3D bunion correction system known as "Lapiplasty" [2] - As a result of competitive pressures, Treace Medical's revenue declined, prompting the company to accelerate plans for an alternative product to osteotomy [2] - Defendants allegedly made materially misleading positive statements regarding the company's business, operations, and future prospects [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until June 10, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4]

Group 1 - The Rosen Law Firm is reminding purchasers of Treace Medical Concepts, Inc. securities of the lead plaintiff deadline on June 10, 2025, for a class action lawsuit [1] - Investors who purchased Treace Medical securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting the Rosen Law Firm [3][6] Group 2 - The lawsuit alleges that during the class period, Treace Medical made false or misleading statements regarding competition affecting the demand for its primary product, the Lapiplasty 3D Bunion Correction System [5] - It is claimed that Treace Medical's revenue declined, necessitating an acceleration of plans to offer an alternative product to osteotomy [5] - The lawsuit asserts that the positive statements made by Treace Medical about its business and prospects were materially misleading and lacked a reasonable basis [5] Group 3 - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements for investors, including over $438 million in 2019 and has been ranked highly in securities class action settlements since 2013 [4]

Core Viewpoint - Treace Medical Concepts, Inc. has filed a lawsuit against Zimmer Biomet Holdings, Inc. and Paragon 28, Inc. for patent infringement related to its Lapiplasty® 3D Bunion Correction® technologies, seeking injunctive relief and damages [1]. Group 1: Company Overview - Treace Medical Concepts is a medical technology company focused on advancing surgical treatment for bunions and midfoot deformities, with an estimated 67 million Americans affected by bunions, of which 1.1 million are annual surgical candidates [3]. - The company has developed and patented the Lapiplasty® 3D Bunion Correction® System, which addresses the root cause of bunions by correcting deformities in three planes and stabilizing the affected joint [3]. - Treace's patent portfolio includes 80 granted U.S. patents and 26 granted patents worldwide, along with over 150 pending patent applications, highlighting its commitment to innovation and intellectual property protection [2]. Group 2: Legal Action - The lawsuit filed by Treace aims to protect its significant investments in research and technology, emphasizing the importance of enforcing intellectual property rights to foster continued innovation [2]. - The legal action is seen as a necessary step to safeguard the company's pioneering position in the surgical treatment of bunions [2].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Treace Medical Concepts, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements and undisclosed competition impacts on the company's primary product [3][5]. Group 1: Allegations and Impact - The complaint alleges that Treace Medical and its executives made false or misleading statements regarding the demand for their primary product, the Lapiplasty 3D Bunion Correction System, and failed to disclose competitive pressures affecting revenue [5]. - Following a press release on May 7, 2024, the company lowered its full-year 2024 revenue guidance from a range of $220 million to $225 million down to $201 million to $211 million, indicating significant revenue decline [6]. - The stock price of Treace Medical fell by $6.95, or nearly 63%, closing at $4.17 per share on May 8, 2024, following the announcement of the lowered revenue guidance [7]. Group 2: Legal Proceedings - Investors who purchased Treace Medical securities between May 8, 2023, and May 7, 2024, are encouraged to discuss their legal rights and options, with a deadline of June 10, 2025, to seek the role of lead plaintiff in the federal securities class action [2][3]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [8]. - Faruqi & Faruqi is also seeking information from whistleblowers, former employees, and shareholders regarding Treace's conduct [9].

Core Insights - Pomerantz LLP is investigating claims on behalf of investors of Treace Medical Concepts, Inc. regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1] Financial Performance - Treace Medical lowered its full-year 2024 revenue guidance from a range of $220 million to $225 million down to a range of $201 million to $211 million [3] - Following this announcement, Treace Medical's stock price fell by $6.95, nearly 63%, closing at $4.17 per share on May 8, 2024, with unusually high trading volume [4] Legal Context - The Pomerantz Firm is recognized for its expertise in corporate, securities, and antitrust class litigation, having a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [5]